Recent Research Analysts’ Ratings Changes for Eton Pharmaceuticals (ETON)

Posted by on Sep 2nd, 2026

A number of firms have modified their ratings and price targets on shares of Eton Pharmaceuticals (NASDAQ: ETON) recently:

  • 8/24/2026 – Eton Pharmaceuticals was upgraded by Zacks Research from “strong sell” to “hold”.
  • 8/14/2026 – Eton Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $60.00 to $68.00. They now have a “buy” rating on the stock.
  • 8/14/2026 – Eton Pharmaceuticals had its “buy” rating reaffirmed by B. Riley Financial, Inc.. They now have a $70.00 price target on the stock, up from $40.00.
  • 8/14/2026 – Eton Pharmaceuticals had its price target raised by HC Wainwright from $65.00 to $70.00. They now have a “buy” rating on the stock.
  • 8/11/2026 – Eton Pharmaceuticals had its price target raised by HC Wainwright from $57.00 to $65.00. They now have a “buy” rating on the stock.
  • 7/28/2026 – Eton Pharmaceuticals had its price target raised by Craig Hallum from $40.00 to $62.00. They now have a “buy” rating on the stock.
  • 7/17/2026 – Eton Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 7/16/2026 – Eton Pharmaceuticals is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $60.00 price target on the stock.
  • 7/16/2026 – Eton Pharmaceuticals was upgraded by Canaccord Genuity Group Inc. to “strong-buy”.
  • 7/13/2026 – Eton Pharmaceuticals was downgraded by Zacks Research from “hold” to “strong sell”.

Insider Transactions at Eton Pharmaceuticals

In related news, Director Jennifer Mckie Adams sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at approximately $1,624,000. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David Krempa sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the sale, the insider owned 37,025 shares of the company’s stock, valued at approximately $2,409,216.75. This represents a 40.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 125,000 shares of company stock valued at $6,204,250 over the last three months. 16.49% of the stock is owned by corporate insiders.

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.

Recommended Stories

Receive News & Ratings for Eton Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.